Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $14.98 USD
Change Today +0.43 / 2.96%
Volume 125.4K
MRNS On Other Exchanges
As of 8:10 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

marinus pharmaceuticals inc (MRNS) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/24/15 - $17.60
52 Week Low
09/22/14 - $5.49
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

marinus pharmaceuticals inc (MRNS) Related Businessweek News

No Related Businessweek News Found

marinus pharmaceuticals inc (MRNS) Details

Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing neuropsychiatric therapeutics. It is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat patients with refractory focal onset seizures; and is in Phase II clinical trials for the treatment of orphan disease, as well as is in Phase II crossover clinical study to treat behaviors in Fragile X Syndrome, an orphan indication. The company is also developing an IV formulation for use in the hospital setting to control acute seizures. It has a collaboration agreement with NovaMedica, LLC; and license agreement with Purdue Neuroscience Company. Marinus Pharmaceuticals, Inc. was founded in 2003 and is based in Radnor, Pennsylvania.

9 Employees
Last Reported Date: 05/14/15
Founded in 2003

marinus pharmaceuticals inc (MRNS) Top Compensated Officers

Executive Chairman, Chief Executive Officer a...
Total Annual Compensation: $455.0K
Chief Financial Officer, Vice President, Trea...
Total Annual Compensation: $405.0K
Chief Medical Officer
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

marinus pharmaceuticals inc (MRNS) Key Developments

Marinus Pharmaceuticals, Inc. Announces Results of Phase 2 Clinical Trial in PCDH19 with Ganaxolone

Marinus Pharmaceuticals, Inc. announced that Jozef Gecz, Ph.D., Professor of Human Genetics at the Department of Pediatrics, University of Adelaide, published data in the June issue of Human Molecular Genetics, supporting the role for neurosteroids in the pathophysiology of PCDH19 female epilepsy. Marinus is currently conducting a Phase 2 clinical trial in PCDH19 with ganaxolone, a small molecule that is a synthetic analog of the endogenous neurosteroid allopregnanolone, and received orphan designation from the United States Food and Drug Administration for PCDH19 female epilepsy earlier this year. In his research, Dr. Gecz used primary skin fibroblasts from 12 PCDH19 affected females and three transmitting males, to show that steroid metabolism and neurosteroid metabolism is associated with PCDH19 female epilepsy. Dr. Gecz identified two genes, AKR1C2 and AKR1C3, which code for crucial neurosteroid-metabolizing enzymes and showed that downregulation of the AKR1C3 and AKR1C2 genes leads to allopregnanolone deficiency in the blood of all PCDH19 females tested. Dr. Gecz then studied nine additional PCDH19 females and age-matched control subjects to measure their blood allopregnanolone levels using three alternative assays. While allopregnanolone levels varied with age, all PCDH19 females tested had lower blood allopregnanolone levels than their age-matched controls. In conclusion, the study showed that the deficiency of neurosteroid allopregnanolone, one of the most potent GABA receptor modulators, may contribute to PCDH19 female epilepsy. Marinus is currently enrolling patients in its Phase 2 clinical study in PCDH19. The study is designed to enroll approximately 10 female pediatric patients between the ages of 2 and 10 years old, with a confirmed PCDH19 genetic mutation. After establishing baseline seizure frequency, patients are being treated with ganaxolone, administered as either oral liquid suspension or capsules, for up to 26 weeks. The primary endpoint of the study is percent change in seizure frequency per 28 days relative to baseline.

Marinus Pharmaceuticals, Inc. Presents at JMP Securities Life Sciences Conference, Jun-23-2015 01:00 PM

Marinus Pharmaceuticals, Inc. Presents at JMP Securities Life Sciences Conference, Jun-23-2015 01:00 PM. Venue: The St. Regis New York, 2 East 55th Street, New York, NY 10022, United States. Speakers: Edward F. Smith, Chief Financial Officer, Vice President, Treasurer and Secretary.

Marinus Pharmaceuticals, Inc. Announces Unaudited Earnings Results for First Quarter Ended March 31, 2015

Marinus Pharmaceuticals, Inc. announced unaudited earnings results for first quarter ended March 31, 2015. For the quarter, the company reported loss from operations of $6,915,000, interest income of $14,000, net loss of $7,007,000, net loss applicable to common stockholders of $7,007,000 or $0.5 basic and diluted per share, compared to the loss from operations of $2,665,000, interest income of $4,000, net loss of $2,235,000, net loss applicable to common stockholders of $3,306,000 or $7.09 basic and diluted per share, for the same quarter a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRNS:US $14.98 USD +0.43

MRNS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Novartis AG SFr.98.85 CHF +1.00
View Industry Companies

Industry Analysis


Industry Average

Valuation MRNS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 5.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MARINUS PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at